Floatz logo

INDOMETACINUM

Migraine Disorder

Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaSmall moleculePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

107 Active assets in the Migraine Disorder cohort.

Asset / SponsorPhaseRating
Atogepant
Stanford University
Phase 4A
Rizatriptan
Antonios Likourezos
Phase 4A
Zolmitriptan
Zosano Pharma Corporation
Phase 4A
Naproxen
IRCCS San Raffaele Roma
Phase 4A
mk-1602
H. Lundbeck A/S
Phase 4BBB

View all 50 →

Same molecule, other indications

INDOMETACINUM is also rated in:

prostate cancerDormant
B
Indicative ·
63 / 100
View asset →
cutaneous melanomaDormant
B
Indicative ·
57 / 100
View asset →
prostate adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →